In conclusion, we demonstrated that the induction of PML-RARA targeted human CD34+ cells, including CMP, and led to their ability to cause APL, and that CD34− APL cells have the capability of maintaining the disease. The gene discussed is CD34; the disease is acute promyelocytic leukemia.